discuss management
move floor set focu
addit color management chang discuss morn
chang continu occur top jon giacomin ceo medic
busi leav compani mid-august stephen mason presid cah at-
solut busi promot ceo role medic segment
promis see compani seemingli prepar giacomin exit
quick intern promot stephen mason replac unfortun
giacomin exit medic segment also come alongsid cah cfo exit
announc last week expect occur earn
alongsid announc compani also indic would meet least
mid-point compani guidanc suggest ep ep
in-lin street expect discuss june quarter outlook detail
cardin rest pharmaceut suppli channel report publish
overnight healthcar distribut subsector channel check
given turnov cfo level chang occur
medic segment today news may lead investor greater concern
regard medic busi compani outlook discuss
compani morn note announc time cfo
medic segment ceo departur coincident thu seemingli impli
chang indic system problem compani
investor may postul conserv trim ep estim
street current assum ebit declin
pharma distribut segment ebit growth previous
ebit growth medic segment growth previous lower
pt base new ep
quarterli annual ep usd
consensu number refinitiv receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
lower usd
return equiti ttm
link barclay live interact chart
equal weight equal weight
compani continu go transit relat
medic busi core drug
distribut busin continu lap headwind
upsid case see gener price improv
brand inflat come slightli exoecatuib
lead multipl expans
downsid case see gener price continu
remain heavili deflationari slower expect
improv seen cordi busi lead
lower price multipl contract
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
singl digit growthlow singl digit growthmid singl digit growthmid singl digit growthnon-gaap effect tax expens milnon-gaap dilut milcapit milpharma segmentrevenu growthlow singl digit growthlow singl digit growthmid high singl digit growthmid high singl digit growthprofit ebit growthhigh singl low doubl digit declinehigh singl low doubl digit declinehigh singl low doubl digit declinehigh singl low doubl digit declinegener pricingsimilar pricingmid-singl digitmid-singl digitmid-singl digitmid-singl digitmed segmentrev growthlow singl digit growthlow singl digit growthapproxim flatapproxim flatebit growthmid high singl digit growthmid high singl digit growthmid high singl digit growthlow mid singl digit declin barclay cardin
 quarterli revenu model mil cahcahcahcahcahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin quarterli oper profit mil cahcahcahcahcahcahcahoper profit ebit ebit ebit ebit barclay
 quarterli incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
 annual revenu model mil cahcahcahrevenu revenuepharmaceut distribut elimin growthpharmaceut distribut elimin total revspharmaceut distribut elimin annual oper profit mil cahcahcahoper profit ebit ebit ebit ebit barclay
 annual incom statement distribut sell addback oper addback check excl intang asset ens rate minor check ep fulli dilut share growth distribut sell per barclay
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
http //publicresearch barclay com altern send written request barclay research complianc seventh avenu floor
new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ firm total
revenu portion gener invest bank activ profit revenu market busi
potenti interest firm invest client research respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit accept
payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link analysi
quantit analysi trade idea recommend contain one type barclay research may differ contain
type barclay research whether result differ time horizon methodolog otherwis
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas refer
procedur pleas
price sourc refinitiv last avail close price relev trade market unless anoth time sourc indic
